8JT3 image
Deposition Date 2023-06-21
Release Date 2023-08-02
Last Version Date 2024-05-08
Entry Detail
PDB ID:
8JT3
Keywords:
Title:
Crystal structure of aminotransferase CrmG from Actinoalloteichus sp. WH1-2216-6 in complex with amino donor L-Arg
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.35 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:CrmG
Chain IDs:A, B (auth: C), C (auth: B), D
Chain Length:523
Number of Molecules:4
Biological Source:Actinoalloteichus sp. 2216-6
Primary Citation
Co-crystal structure provides insights on transaminase CrmG recognition amino donor L-Arg.
Biochem.Biophys.Res.Commun. 675 41 45 (2023)
PMID: 37451216 DOI: 10.1016/j.bbrc.2023.07.009

Abstact

ω-transaminase has attracted growing attention for chiral amine synthesis, although it commonly suffers from severe by-product inhibition. ω-transaminase CrmG is critical for the biosynthesis of Caerulomycin A, a natural product that possesses broad bioactivity, including immunosuppressive and anti-cancer. Compared to L-Arg, amino donor L-Glu, L-Gln or L-Ala is more preferred by CrmG. In this study, we determined the crystal structure of CrmG in complex with amino donor L-Arg, unveiling the detailed binding mode. Specifically, L-Arg exhibits an extensive contact with aromatic residues F207 and W223 on the roof of CrmG active site via cation-π network. This interaction may render the deamination by-product of L-Arg to be an inhibitor against PMP-bound CrmG by stabilizing its flexible roof, thus reducing the reactivity of L-Arg as an amino donor for CrmG. These data provide further evidence to support our previous proposal that CrmG can overcome inhibition from those by-products that are not able to stabilize the flexible roof of active site in PMP-bound CrmG. Thus, our result can not only facilitate the biosynthesis of CRM A but also be beneficial for the rational design of ω-transaminase to bypass by-product inhibition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback